Wolverine Peptide Stack (BPC-157 + TB-500): What the Research Actually Shows

Wolverine Peptide Stack (BPC-157 + TB-500): What the Research Actually Shows
Paulo Hariss
November 11, 2026
Reading Time: 18 mins
Science & Medicine Tissue Repair Peptide Stacks Research Guide
Research Guide

Wolverine Peptide Stack (BPC-157 + TB-500): What the Research Actually Shows

The Wolverine stack, or Wolverine peptide stack, is the popular name for combining BPC-157 with TB-500. This guide explains what each peptide does in published studies, what happened when researchers finally tested the combination, the doses and study durations used, reported side effects, and where the 2026 regulatory picture stands.

By Medical Team of Ordinary Peptides · Updated
Quick answer

The Wolverine stack is BPC-157 plus TB-500, two peptides studied separately for tendon, muscle and wound repair in animals. The only controlled study of the combination (rats, Achilles tendon, 2026) found no extra benefit over either peptide alone. There are no human trials of the stack, and both peptides are banned in sport.

What the Wolverine Stack Is

"Wolverine stack" is an informal name, borrowed from the comic-book character known for rapid healing, for the pairing of two research peptides: BPC-157, a 15-amino-acid fragment derived from a protein in human gastric juice, and TB-500, a synthetic peptide related to the natural repair protein thymosin beta-4. The name is marketing, not science: no journal or regulator uses it.

The idea behind the stack is that the two peptides act on different stages of tissue repair, so together they might cover more of the healing process. That idea is reasonable on paper. As this guide shows, it has only been tested directly once, and the result was not what the marketing suggests.

This article focuses on the combination. For a side-by-side comparison of the two peptides, see BPC-157 vs TB-500: evidence, safety and FDA status.

BPC-157 in Published Research

BPC-157 has one of the largest animal literatures of any research peptide, most of it from a single group at the University of Zagreb (see the history of BPC-157). In tendon research specifically, the key findings are:

  • Achilles tendon transection (rats, 2003). Daily intraperitoneal BPC-157 improved functional, biomechanical and microscopic healing of a cut Achilles tendon compared with saline, where control animals healed poorly [1].
  • Tendon-to-bone healing (rats, 2006). BPC-157 improved load to failure, stiffness and function after the Achilles tendon was detached from bone, and reduced the healing impairment caused by a corticosteroid [2].
  • Mechanism in tendon cells (2011). In cultured rat tendon fibroblasts, BPC-157 increased outgrowth from tendon explants, cell survival under oxidative stress and cell migration, apparently through the FAK-paxillin pathway. It did not directly increase cell proliferation [3].

A 2025 systematic review in HSS Journal screened the full BPC-157 literature for orthopaedic use and included 36 studies: 35 preclinical and only one clinical [4]. The reviewers concluded that BPC-157 "shows promise" for musculoskeletal recovery while highlighting the lack of human safety data and the risks of unregulated products.

TB-500 and Thymosin Beta-4 in Research

A naming problem worth knowing about

"TB-500" is a market name, and it is used for two different molecules. Thymosin beta-4 (Tβ4) is a natural 43-amino-acid protein found in almost every cell. The anti-doping literature and the FDA define TB-500 as a much shorter synthetic fragment: the acetylated actin-binding sequence Ac-LKKTETQ (residues 17-23 of Tβ4) [7]. Some suppliers sell full-length Tβ4 under the TB-500 name. For research, the Certificate of Analysis and the stated sequence matter more than the label. Our catalog lists the fragment separately as Frag 17-23.

What the studies show

  • Skin wounds (rats, 1999). Topical or intraperitoneal Tβ4 increased re-epithelialization of full-thickness wounds by 42% at day 4 and up to 61% at day 7 versus saline, with increased collagen deposition and angiogenesis in treated wounds [5].
  • The active region (2006). Tβ4 increased matrix metalloproteinase expression during wound repair, and this activity was traced to its central actin-binding domain, the same region that TB-500 copies [6].

Most of the evidence is for full-length Tβ4, not the short fragment. The FDA made this point explicitly in its July 2026 review: human trials of thymosin beta-4 are not evidence for TB-500 [9].

Why Researchers Combine Them

The rationale for the stack comes from the different mechanisms reported for each peptide in animal and cell studies:

Feature BPC-157 TB-500 / Tβ4
Origin 15-amino-acid fragment of a gastric juice protein Fragment of thymosin beta-4 (actin-binding region)
Main reported mechanism Fibroblast migration and survival (FAK-paxillin), VEGF-linked angiogenesis G-actin sequestration, cell migration, MMP expression
Best-studied tissues Tendon, ligament, muscle, gut mucosa Skin wounds, cornea, heart (mostly full-length Tβ4)
Human data Three small uncontrolled pilots None for the fragment; small trials for full-length Tβ4

The argument is that BPC-157 supports local blood supply and fibroblast activity while TB-500 helps repair cells move into damaged tissue. The weakness of the argument is that both peptides converge on similar downstream processes, such as angiogenesis and cell migration, so their effects may overlap rather than add up.

What Is the Wolverine Stack Studied For?

Searches for "Wolverine stack benefits" usually mean one question: what is it used for? In research terms, the answer is the tissues each peptide has been tested on. The evidence level differs a lot between them.

Research area BPC-157 TB-500 / Tβ4 Combination
Tendon and ligament injury Several rat studies (Achilles transection, tendon-to-bone, ligament) [1][2] One rat Achilles study [8] One rat study, no added benefit [8]
Muscle injury Rat crush and transection models [13] Limited Not studied
Skin wounds Rat models Rat and mouse wound models, mostly full-length Tβ4 [5] Not studied
Gut lining Main focus of early research; FDA reviewed it for ulcerative colitis [9] Not a focus Not studied
Pain in humans Small uncontrolled pilots only None for the fragment Not studied

In short, the "benefits" attributed to the Wolverine stack are the animal findings for each peptide added together. None of them have been shown in a controlled human trial, alone or combined.

The First Study of the Combination

For years the Wolverine stack had no direct evidence at all: every claim of "synergy" was extrapolated from separate studies of each peptide. In 2026, an orthopaedic research team published the first controlled comparison of BPC-157, TB-500 and their combination [8].

Biçer et al. · Joint Diseases and Related Surgery, 2026

Design: 32 male rats with a repaired Achilles tendon rupture, four groups of 8: control, BPC-157 (10 µg/kg/day), TB-500 (60 µg/kg/day) and both together. Intraperitoneal, once daily for 4 weeks.

Results: load to failure was higher with both peptides, but statistically significant only for TB-500. TB-500 also had significantly better histology scores. The combination did not give additional benefit compared with either peptide alone.

Limits: small, exploratory, one dose level, one tissue, rats only.

One rat study cannot settle the question. But it is the only direct test of the stack published so far, and it did not support the idea that the two peptides together outperform either one. The authors suggested the lack of an additive effect may reflect the peptides acting on shared pathways.

The only controlled test of the Wolverine stack found no added benefit from combining BPC-157 with TB-500.

Wolverine Stack Dosage Chart: Doses Used in Published Research

The table lists doses from the studies cited in this guide. They come from animal models (dosed per kilogram of body weight) and one small human safety pilot. They are not human dosing recommendations, and animal doses do not convert directly to people. The "Wolverine stack dosage charts" and "protocols" that circulate online, often with fixed daily microgram amounts, are not taken from controlled studies: no human dosing chart for the stack has ever been tested.

Study Model Substance, dose and route Duration
Staresinic et al., 2003 [1] Rat, Achilles transection BPC-157 10 µg, 10 ng or 10 pg/kg, i.p., once daily Up to 14 days
Krivic et al., 2006 [2] Rat, tendon-to-bone detachment BPC-157 10 µg, 10 ng or 10 pg/kg, i.p., once daily Up to 21 days
Malinda et al., 1999 [5] Rat, full-thickness skin wound Thymosin beta-4, topical or i.p. 7 days of assessment
Biçer et al., 2026 [8] Rat, Achilles rupture repair BPC-157 10 µg/kg/day + TB-500 60 µg/kg/day, i.p. (alone and combined) 4 weeks
Lee & Burgess, 2025 [10] 2 healthy adults (safety only) BPC-157 10 mg then 20 mg, intravenous infusion 2 days

For lab work with lyophilized peptides, our peptide reconstitution calculator converts vial amount and diluent volume into concentration.

How Long Do Results Take? Study Timelines

"How long does the Wolverine stack take to work" and "before and after" are common searches, but published research cannot answer them for people. What the studies do show is the time frames they measured:

  • BPC-157 in tendon models: functional and biomechanical differences were measured from day 4 to day 14 after Achilles transection [1] and up to day 21 after tendon-to-bone detachment [2].
  • Thymosin beta-4 in skin wounds: faster re-epithelialization was measured at days 4 and 7 [5].
  • The combination: outcomes were assessed once, at 4 weeks [8].

"Cycle length" in research is simply the study duration, typically 2 to 4 weeks in rats. Before-and-after stories online are individual anecdotes with no control group, unknown product purity and no way to separate the peptide's effect from normal healing or physical therapy.

Blend vs Separate Vials, and Oral Forms

Pre-mixed blend or two vials?

Research suppliers offer the stack either as a single blend vial containing both peptides or as two separate vials. Chemically the peptides are the same. The practical differences for a lab are:

  • Blend: fixed ratio, one reconstitution step, one Certificate of Analysis that should list the amount of each peptide.
  • Separate vials: each peptide can be dosed independently, which is what the only combination study did (BPC-157 and TB-500 at different doses per kilogram) [8].

For blends, check that the label and COA state the milligrams of each peptide, not just the total. Our reconstitution calculator gives the concentration per mL for any vial amount and diluent volume.

Oral and capsule forms

BPC-157 is unusually stable in gastric juice, and several rat studies from the Zagreb group gave it in drinking water as well as by injection [13]. This is why BPC-157 oral capsules exist as a research format. TB-500 has no published oral research, so "oral Wolverine stack" products rely on BPC-157 data alone.

Human Evidence and Wolverine Stack Side Effects

There are no published human studies of BPC-157 and TB-500 together. For each peptide separately:

  • BPC-157: three small, uncontrolled pilot studies with roughly 30 participants in total, all from one author group. The most recent gave intravenous BPC-157 (10 mg, then 20 mg) to two healthy adults and reported no adverse effects or abnormal lab results [10]. Two people over two days cannot establish safety.
  • TB-500 fragment: no completed human efficacy or safety trials. Small clinical trials exist for full-length thymosin beta-4 (eye and skin), which is a different molecule [9].

Reported and possible side effects

Searches for "Wolverine stack side effects" mostly lead to anecdotal reports such as injection-site irritation, headache or lightheadedness. These come from forums and clinic marketing, not from controlled studies, so their frequency is unknown. The published BPC-157 pilots were too small to detect anything but very common, acute reactions.

Open safety questions include long-term effects, the theoretical concern that peptides promoting blood-vessel growth could affect tumor growth, immune reactions, and the purity of unregulated products. We cover the BPC-157 side in detail in BPC-157 side effects: reported and unknown risks.

How to Check Research-Grade Quality

Because neither peptide is an approved drug, quality depends entirely on the supplier. FDA reviewers specifically raised impurity and characterization concerns for BPC-157 [9]. For research material, look for:

  • Batch-specific COA with HPLC purity (typically ≥98-99%) and mass spectrometry confirming identity.
  • The exact sequence for TB-500, so you know whether it is the Ac-LKKTETQ fragment or full-length thymosin beta-4.
  • Per-peptide amounts on blend labels, and lyophilized (freeze-dried) powder with storage instructions.
  • "Research use only" labeling, with no human dosing claims.

FDA and WADA Status in 2026

  • Not FDA-approved. Neither BPC-157 nor TB-500 is an approved drug for any use.
  • Compounding: both were placed in FDA's Category 2 ("significant safety risks") in 2023 and removed in April 2026 after their nominations were withdrawn. On July 23, 2026, the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend each for the 503A bulks list, against the advice of FDA staff reviewers [9]. On October 28, 2026, HHS announced interim enforcement discretion for 503A pharmacies compounding six peptides, including BPC-157 and TB-500, while formal rulemaking continues [11].
  • No compounded "stacks." The HHS policy requires a compounded product to contain only one of the listed peptides, so a pre-mixed BPC-157 + TB-500 product falls outside it [11].
  • Sport: under the 2026 WADA Prohibited List, BPC-157 is named under S0 (non-approved substances), and "thymosin-β4 and its derivatives, e.g. TB-500" are listed under S2. Both are prohibited at all times [12].

Frequently Asked Questions

What is the Wolverine stack?

It is the popular name for combining two research peptides, BPC-157 and TB-500, which have each been studied for tendon, muscle and wound repair in animal models. The name refers to the comic-book character's fast healing and is not a scientific term.

Does combining BPC-157 and TB-500 work better than either alone?

There is no evidence that it does. The only controlled study of the combination, a 2026 rat Achilles tendon study, found that the combined treatment gave no additional benefit over either peptide alone. Claims of synergy are based on theory, not data.

What doses of the Wolverine stack were used in research?

In the 2026 combination study, rats received BPC-157 at 10 µg/kg/day and TB-500 at 60 µg/kg/day by intraperitoneal injection for four weeks. These are animal doses per kilogram of body weight. There is no validated human dose for the stack.

Is TB-500 the same as thymosin beta-4?

Not exactly. Thymosin beta-4 is a natural 43-amino-acid protein. TB-500 is usually defined as a short synthetic fragment of it, the actin-binding sequence Ac-LKKTETQ, although some products sold as TB-500 contain the full protein. Evidence for thymosin beta-4 does not automatically apply to the fragment.

Is the Wolverine stack FDA-approved or legal for athletes?

Neither peptide is FDA-approved. Since October 2026, U.S. 503A pharmacies may compound each peptide separately under an interim enforcement policy, but not combined products. Both are prohibited at all times under the 2026 WADA Prohibited List.

How long does the Wolverine stack take to work?

There is no human data to answer this. In rat studies, BPC-157 effects on tendon healing were measured between day 4 and day 21, and the only combination study assessed results at 4 weeks. Online timelines are anecdotal.

What are the side effects of the Wolverine stack?

No study has measured side effects of the combination. Reported effects such as injection-site irritation come from anecdotes. Unknowns include long-term safety, immune reactions, effects related to blood-vessel growth, and contamination in unregulated products.

Is a BPC-157 + TB-500 blend different from two separate vials?

The peptides are the same. A blend has a fixed ratio and one reconstitution step; separate vials let researchers vary each peptide independently, as the 2026 combination study did. A blend label should state the milligrams of each peptide.

Are there human studies of BPC-157 and TB-500 together?

No. BPC-157 has three small uncontrolled human pilot studies, and the TB-500 fragment has no completed human trials. No study has tested the two together in people.

Related Research

Research use only

All products are sold strictly for laboratory research. Not for human or veterinary use. This article summarizes published scientific literature and is not medical advice.

Sources

  1. Staresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. pubmed.ncbi.nlm.nih.gov/14554208
  2. Krivic A et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. pubmed.ncbi.nlm.nih.gov/16583442
  3. Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. pubmed.ncbi.nlm.nih.gov/21030672
  4. Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. pubmed.ncbi.nlm.nih.gov/40756949
  5. Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. pubmed.ncbi.nlm.nih.gov/10469335
  6. Philp D et al. Thymosin beta4 promotes matrix metalloproteinase expression during wound repair. J Cell Physiol. 2006. pubmed.ncbi.nlm.nih.gov/16607611
  7. Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012.
  8. Biçer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. jointdrs.org/abstract/1851
  9. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document, July 23-24, 2026. fda.gov/media/193342
  10. Lee E et al. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20-24. pubmed.ncbi.nlm.nih.gov/40131143
  11. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, October 28, 2026; summary: Buchanan Ingersoll & Rooney. bipc.com
  12. World Anti-Doping Agency. The 2026 Prohibited List (in force January 1, 2026), sections S0 and S2. wada-ama.org
  13. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. pubmed.ncbi.nlm.nih.gov/30915550